1038 results about "Polyarthritis Rheumatica" patented technology

The invention relates to the field of traditional Chinese medicine effective component new dosage form pharmaceutical preparations, and discloses an M2 type macrophage membrane coated ROS responsive bionic nano drug delivery system, preparation and application. Mesoporous silica is used as a core to load a traditional Chinese medicine effective component, namely tripterine, and lipid components, namely PEGylated distearoyl phosphatidyl ethanolamine (DSPE-PEG), dioleoyl lecithin (DOPC), cholesterol and the like, are used as raw materials to prepare a ROS-responsive lipid coating, so that ROS-responsive tripterine mesoporous silica is formed. And then realizing bionic fusion with the M2 type macrophage membrane on the outer layer through an ultrasonic coating technology to prepare the M2 type macrophage membrane coated ROS responsive bionic mesoporous silica nano drug delivery system. The invention can realize targeted therapy of rheumatoid arthritis, and has the advantages of biological safety and the like.

The invention discloses preparation and application of bionic cerium-based polyphenol nano-enzyme for treating rheumatoid arthritis, and belongs to the field of medical preparations. The method comprises the following steps: respectively complexing cerium ions and tannic acid or epicatechin gallate to prepare cerium-based polyphenol nano-enzyme, and then preparing the cerium-based polyphenol nano-enzyme wrapped by a macrophage membrane. And loading the cerium-based polyphenol nano-enzyme wrapped by the macrophage membrane into the hydrogel to prepare the hyaluronic acid-based hydrogel. The cerium-based polyphenol nano-enzyme and the hyaluronic acid-based hydrogel are characterized, it is verified that the cerium-based polyphenol nano-enzyme and the hyaluronic acid-based hydrogel are successfully synthesized, the particle size of CeTA is about 22 nm, the particle size of M-CeTA is increased to 273 nm, the particle size of CeECG is about 95 nm, and the particle size of M-CeECG is increased to 292 nm. In-vitro experiments prove that the M-CeTA and the M-CeECG do not show obvious cytotoxicity when being less than 80 mu g / mL, and have an obvious inhibition effect on expression of cell inflammatory factors on inflammatory cells.

Methods and devices are provided for the non-invasive treatment of diseases or disorders, such as Alzheimer's disease, Parkinson's disease, rheumatoid arthritis (RA), multiple sclerosis, postoperative cognitive dysfunction, or postoperative delirium. A method for comprises positioning an electrode in contact with an outer skin surface of a neck of the patient and transmitting, via the electrode, an electric current transcutaneously and non-invasively through the outer skin surface of the neck of the patient to generate an electrical impulse at or near a vagus nerve within the patient. The electrical impulse comprises bursts of 2 to 20 pulses with each of the bursts comprising a frequency from about 15 Hz to about 50 Hz and with each of the pulses comprising a duration from about 20 microseconds to about 1000 microseconds.

The invention provides a composition capable of penetrating an intestinal barrier by oral administration. The composition contains a carrier or an auxiliary material of a targeted Microflod cell Dectin-1 receptor, and one or / and a plurality of medicinal components / components, wherein the carrier or the auxiliary material of the target Microflood cell Dectin-1 receptor is beta-glucan, and the carrier or the auxiliary material of the target Microflood cell Dectin-1 receptor is beta-glucan. The effective components / components are traditional Chinese medicine effective components / components, or / and probiotics, or / and chemical medicine components, or / and biological medicines. The invention relates to a composition capable of realizing oral administration and penetrating through an intestinal barrier, which is based on the discovery of the inventor that the composition reaches colon through gastrointestinal tracts, targets colon Microflood cells, is taken by the Microflood cells, penetrates through the intestinal barrier and enters immune tissue Colonic Patches of a colon submucosa. Based on the research, the composition disclosed by the invention can be used for treating various diseases, such as ulcerative colitis, Crohn's disease, colon cancer, rheumatoid arthritis or bacterial pneumonia after being orally taken and absorbed by rectum.

The invention relates to an active oxygen responsive triptolide prodrug immunoregulation hydrogel preparation as well as a preparation method and application thereof. Triptolide is coupled with an active oxygen responsive group to synthesize a triptolide derivative; then, the triptolide derivative is coupled with polypeptide, and a polypeptide-reactive oxygen responsive group-triptolide conjugate is obtained; then dissolving the polypeptide-active oxygen responsive group-triptolide conjugate in a solvent, standing, and carrying out self-assembly to obtain a triptolide prodrug nanofiber solution; finally, an immunomodulator is added into the triptolide prodrug nanofiber solution for incubation, and the active oxygen responsive triptolide prodrug immunoregulation hydrogel preparation is obtained. The hydrogel preparation disclosed by the invention can responsively release the medicine triptolide and the immunomodulator at the focus part of rheumatoid arthritis, so that the medicine accumulation of non-target organs is reduced, the safety and effectiveness of treatment are improved, and the progress of diseases is effectively controlled.

The invention provides an organ chip unit for simulating the pathogenesis of rheumatoid arthritis, and belongs to the technical field of cell culture. The chip comprises a top-layer chip, a bottom-layer chip and a middle microporous membrane, the top-layer chip and the bottom-layer chip are separated by the middle microporous membrane, and the middle microporous membrane is used for enabling cells in a cell culture space of the top-layer chip and cells in a cell culture space of the bottom-layer chip not to be in direct contact, but interaction of signal molecules and substance exchange can be carried out; synovial cells and cartilage cells are injected into the bottom-layer chip or the top-layer chip to be cultured. According to the invention, multi-cell three-dimensional co-culture can be realized. Through the additional stress stimulation co-culture part, the influence of pressure or tension on the cell environment can be judged, and the actual condition that rheumatoid arthritis joints receive pressure or tension for a long time can be simulated. The synovial cells and the cartilage cells are used, so that the structure of the inflammation joint in a living body can be truly reflected, and the interaction among various cell tissues can be reflected.

The invention discloses a novel benzofuran component in eupatorium chinense and application of the benzofuran component in anti-inflammatory activity. The obtained compound is separated from an eupatorium chinense extract. The eupatorium chinense root extract is separated by using an extraction method, macroporous adsorption resin impurity removal, Sephadex LH-20 gel column chromatography, high performance liquid chromatography and other methods. According to the present invention, all the separated compounds and the analogues thereof have good inhibition activity on target cyclooxygenase-2 of inflammation-related diseases, and have good inhibition activity on COX-2 enzyme, and the molecular docking experiment results show that the compounds and the target proteins have good binding energy. Therefore, the compound can be used for preparing drugs for treating inflammatory related diseases, or anti-inflammatory and analgesic drugs, or tumor drugs by inhibiting COX-2 enzyme, such as drugs for rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, Alzheimer's disease and the like, and related natural lead compounds are provided.

The present invention relates to double stranded oligonucleotides that are complementary to JAK1, leading to modulation of the expression of JAK1. Modulation of JAK1 expression is beneficial for a range of medical disorders including inflammatory bowel disease, organ transplant rejection, graft-versus-host disease, multiple sclerosis, rheumatoid arthritis (RA), juvenile idiopathic arthritis, psoriasis, dermatitis, diabetic nephropathy, systemic lupus erythematosus (SLE), dry eye disease, cancer, myelofibrosis, and asthma. Also included are compositions comprising the double stranded oligonucleotide and methods of treatment using the double stranded oligonucleotide.

The invention relates to a polypeptide AAMP and application thereof in analgesia and anti-inflammation. The amino acid sequence of the polypeptide AAMP is as shown in SEQ ID NO. 1. The polypeptide AAMP has better anti-inflammatory and analgesic activity; the traditional Chinese medicine composition can relieve pain reaction caused by PNI, and has a good treatment effect on fibromyalgia syndrome, rheumatoid arthritis, rheumatic arthritis, ankylosing spondylitis, nerve injury and other diseases.

The invention discloses a method for predicting periprosthetic infection of an artificial joint after a rheumatoid arthritis operation, and belongs to the technical field of medical treatment, the method can be applied to risk prediction of periprosthetic infection (PJI) of the artificial joint after the rheumatoid arthritis operation, and the method comprises the following steps: carrying out feature selection through a Boruta algorithm; an integrated machine learning algorithm is developed based on a genetic algorithm and an SMOTEENN algorithm in combination with machine learning for risk prediction, so that the accuracy and practicability of PJI risk prediction after joint replacement of a rheumatoid arthritis patient are improved. According to the rheumatoid arthritis artificial joint postoperative periprosthetic infection risk prediction method, a more accurate prediction and personalized treatment scheme can be provided for a doctor, and preoperative management of joint replacement of a rheumatoid arthritis patient is optimized, so that PJI is prevented to the greatest extent, and the joint function and life quality of the patient are improved.

The present invention discloses a dibenzylbutane lignan LCA derivative or a pharmaceutical salt thereof, the structure of which is shown below: #imgabs0# The dibenzylbutane lignan LCA derivative prepared by the present invention has been shown through pharmacological experiments to have significant anti-inflammatory activity, can significantly inhibit the release of inflammatory factors, and can be used to prepare anti-inflammatory drugs for diseases such as rheumatoid arthritis.

The invention belongs to the field of biological medicines, and particularly relates to application of loganic acid in preparation of a medicine for treating arthritis. Specifically, through experimental research of a collagen-induced arthritis mouse model, the loganin acid is found to be capable of remarkably relieving arthritis symptoms, relieving joint swelling, synovitis and cartilage injury in a dose-dependent manner, and reducing the levels of proinflammatory factors TNF-alpha and IL-6 in plasma. By further combining 16S rRNA sequencing analysis, the loganic acid can remarkably regulate the intestinal microbiota structure of arthritis mice, increase the abundance of Lactobacillus murinus in the intestinal tract and promote the generation of tryptophan metabolite indole-3-acetic acid, so that the effect of resisting rheumatoid arthritis is achieved through an intestinal flora dependent mechanism. Therefore, the invention provides a new application of loganin acid in preparation of a medicine for treating arthritis, and the compound has further research and application values as a potential small molecule medicine.

The invention discloses a rheumatoid arthritis foot orthopedic and warm-keeping device, and relates to the technical field of arthritis foot orthopedic, the rheumatoid arthritis foot orthopedic and warm-keeping device comprises a bottom plate, the bottom plate is fixedly connected with a shell, one side of the bottom of the shell is rotatably connected with an insertion rod, one end of the insertion rod is fixedly connected with a turnover plate, the upper surface of the turnover plate is provided with two connecting blocks, and the two connecting blocks are fixedly connected with the bottom of the shell. And the upper surface of the other end of the bottom plate is fixedly connected with a front plate. According to the rheumatoid arthritis foot orthopedic and warm-keeping device, in the process that a patient lifts the instep upwards for the first time, a limiting rod slides into a short groove from a long groove, a sliding rod extrudes a force storage spring to enable the force storage spring to form downward thrust, the downward thrust formed by extruding the force storage spring by the sliding rod is larger, and therefore the foot orthopedic effect is improved. When the patient lifts the instep upwards for the second time, the downward thrust of the force storage spring helps the patient to lift the instep, the burden of instep muscles of the patient is relieved through the stored force of the force storage spring, and the effect of protecting the joints of the patient is achieved.

The disclosure relates to compounds of formula I, wherein X, and R1-R4, n, and m have the meaning given in the specification, and pharmaceutically acceptable salts thereof. The compounds of formula I exhibit GPR 183 antagonistic activity and are thus useful in the treatment or prevention of disorder, condition, or disease where GRP183 antagonist is indicated to be useful, such as e.g. chronic pain e.g osteoarthritis, chronic low back pain, neuropathic pain and immune system diseases e.g inflammatory bowel diseases e.g. Colitis and Chron's diseases, multiple sclerosis, rheumatoid arthritis, inflammatory pulmonary diseases e.g. asthma and psoriasis.

The present invention provides a crystalline compound of the formula:wherein the crystalline compound is useful for treating autoimmune and inflammatory diseases, such as atopic dermatitis, rheumatoid arthritis, and psoriasis.

Provided herein are compositions and methods for the treatment of an autoimmune or inflammatory disease, such as rheumatoid arthritis. Said compositions comprise a TNFR1 inhibitor. Some embodiments comprise combination therapy featuring the TNFR1 inhibitor with at least one additional anti-inflammatory therapeutic agent.

The present disclosure relates to solid-state forms and corresponding pharmaceutical compositions of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, and methods of treatment, including treatment of rheumatoid arthritis and juvenile idiopathic arthritis using the same. The treatment methods generally comprise administering to a patient (e.g., a pediatric patient) a therapeutically effective amount of upadacitinib as a stable liquid pharmaceutical composition or a solid dosage form, at a dose based on patient body weight.

The present disclosure provides methods of treating rheumatoid arthritis comprising administering a MNK inhibitor.

The invention belongs to the technical field of food and medicine, and relates to application of corn germ concentrated powder in improvement of osteoarthritis. The invention particularly relates to application of corn germ concentrated powder, namely corn antioxidant multienzyme, in preparation of medicines or health-care foods for treating rheumatoid arthritis and osteoporosis. In the corn germ concentrated powder, superoxide dismutase / (U / g) is greater than or equal to 8500, glutathione peroxidase / (U / g) is greater than or equal to 5000, and catalase / (U / g) is greater than or equal to 750. The corn germ concentrated powder can also be prepared by the following method: cleaning corn, germinating, adding water into the germinated corn, grinding and pulping, adding a settling agent into the corn steep liquor, standing, taking supernate, adding part of sodium ascorbate, performing temperature-controlled concentration, adding the rest sodium ascorbate and a stabilizer into the concentrated solution, and uniformly mixing to obtain the corn germ concentrated powder. And drying at controlled temperature, crushing, and mixing with a proper amount of silicon dioxide. The prepared corn germ concentrated powder has the effect of resisting rheumatoid arthritis.

The invention relates to a mesenchymal stem cell immunomodulatory function enhancing technology based on gene editing. The invention relates to the field of biomedical engineering and regenerative medicine, and particularly provides a method for enhancing the immune regulation function of mesenchymal stem cells through a CRISPR-Cas9 gene editing technology, and aims at up-regulating IDO1, IL-10 and other key genes in a targeted manner and remarkably improving the excessive immune response inhibition capability of MSCs. The technology can be used for developing high-efficiency and low-toxicity novel cell drugs for treating autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus.

Disclosed in the present invention are a targeted immunotolerance vaccine, a preparation method therefor, and use thereof. The present invention separately modifies a rheumatoid arthritis-related autoantigen peptide and CTLA4 Ig with DSPE-PEG (DP) to prepare a targeted formulation DP-antigen peptide and a targeted formulation DP-CTLA4, which are then mixed to obtain the vaccine. The vaccine described in the present invention, after intravenous injection, binds to albumin in vivo by means of DSPE, "hitchhiking" on albumin to target and enrich in inflammatory lesions, the spleen, the liver, and other tolerance-inducing sites, inhibiting T cell activation, and inducing anergy and apoptosis of rheumatoid arthritis autoantigen-specific T cells, thereby achieving immunotolerance treatment and prevention of rheumatoid arthritis.

The invention belongs to the technical field of biomedicine, and particularly relates to application of DHX58 as a diagnostic marker and a therapeutic target of rheumatoid arthritis. Experiments prove that the DXH58 level in rheumatoid arthritis involved parts such as serum and synovial tissues of rheumatoid arthritis patients is remarkably increased, DHX58 and rheumatoid arthritis are positively correlated, and the DHX58 gene or DHX58 protein can be used as a molecular marker for screening or diagnosis or prognosis evaluation of rheumatoid arthritis. Experiments prove that the targeted DHX58 can be used as an effective way for treating rheumatoid arthritis. The application has important meanings for researching the effect of DHX58 in rheumatoid arthritis, understanding the mechanism of RA disease and developing a new treatment strategy.

The present invention discloses the use of 3,4-dihydropsoralen in the preparation of a drug for preventing or treating rheumatoid arthritis. The present invention simulates RA by constructing TNF-a-induced SW982 cells. The results show that 3,4-dihydropsoralen (DP) can downregulate the mRNA expression of inflammatory factors, chemokines, and matrix degrading enzymes through the IL-17 signaling pathway, and affect the IL-17 signaling pathway and the NF-κB signaling pathway to jointly exert an anti-inflammatory effect, thereby effectively improving rheumatoid arthritis. This provides a theoretical basis for the application of 3,4-dihydropsoralen in the clinical treatment of rheumatoid arthritis and opens up new therapeutic drugs and approaches.

The invention provides a pH response bionic nano system for enhancing photodynamic therapy, preparation and application, and belongs to the field of pharmaceutical preparations, hyaluronic acid is used as an initial carrier to load an endogenous hydrogen sulfide donor SPRC and modify an acid response connexon, and then the hyaluronic acid is crosslinked with a pegylated photosensitizer Ce6 to form acid response nano particles. And finally, coating nano particles with the macrophage membrane through a nano-membrane co-extrusion technology to prepare the pH response type bionic nano system (RAW-HSC) coated with the macrophage membrane. In-vivo and in-vitro experiments show that the pH response type bionic nano system can effectively target an inflammation joint part, a small amount of hydrogen sulfide generated by SPRC release can effectively enhance the photodynamic therapy effect, meanwhile, the pH response type bionic nano system has the advantages of biological safety, pH response release and the like, a new thought is provided for research, development and design of a novel medicament, and the pH response type bionic nano system has wide application prospects. The important significance is realized on the treatment of rheumatoid arthritis.

The invention belongs to the technical field of biological medicines, and discloses a small molecule ligand for targeted administration, a ligand medicine conjugate, a rheumatoid arthritis treatment medicine and application. The small molecule ligand for targeted administration provided by the invention takes a structure as shown in a formula (1) as a linker, and meanwhile, a group M1 derived from a fibroblast activating protein inhibitor is introduced, so that the small molecule ligand can be well applied as a drug delivery platform for RA treatment; the molecular biological activity of the anti-rheumatism medicine is kept, and meanwhile, the anti-rheumatism medicine is fully released in an inflammation joint area, so that a better rheumatoid arthritis treatment effect is achieved, and the anti-rheumatism medicine has a good application prospect. # imgabs0 #

The invention discloses application of probiotic yeast microcapsules in drugs for targeted regulation of inflammatory macrophage immunity, and belongs to the technical field of biological medicines. As a novel medicine, the yeast microcapsule has the characteristics of engineering, convenience, low cost, high patient compliance, high safety and excellent targeting property, can be used as an oral medicine for treating chronic inflammatory disease rheumatoid arthritis, acts on mitochondria through oxidative stress and oxidative phosphoric acid pathways, inhibits excessive activation of macrophages, and has the effect of treating chronic inflammatory disease rheumatoid arthritis. Release of inflammatory factors is reduced, and inflammatory reaction is relieved; the yeast micro-capsule can promote the phagocytosis and antigen presentation function of macrophages and enhance the immune defense capability of a body, so that the immune function of the macrophages is adjusted, and the yeast micro-capsule shows huge potential in preparation of drugs for targeted adjustment of inflammatory macrophage immunity, and has a broad application prospect in preparation of drugs for targeted adjustment of inflammatory macrophage immunity. And a theoretical basis is provided for developing non-invasive, convenient and safe treatment of chronic inflammatory diseases such as rheumatoid arthritis.

The invention relates to a probiotic composition for treating rheumatoid arthritis and application thereof, and relates to the technical field of probiotic compositions.The probiotic composition for treating rheumatoid arthritis is prepared from, by weight, 10-40 parts of lactobacillus johnsonii LBJ 456, 10-30 parts of lactobacillus helveticus HH-LPH17 and 10-30 parts of lactobacillus acidophilus HH-LA26. The bifidobacterium longum subsp. Longum HH-BL18, the bifidobacterium bifidum HH-BB27 and the bifidobacterium longum subsp. Infantis HH-BI27 are prepared from the following raw materials in parts by weight: 10 to 40 parts of bifidobacterium longum subsp. Probiotic strains with specific effects are screened out, the combination proportion of the probiotic strains is optimized, the probiotic composition for treating rheumatoid arthritis is prepared, and a novel safe and effective adjuvant therapy method is provided for treatment of RA.

The present invention relates to novel compounds of general formula (1), their suitable pharmaceutically acceptable salts, their solvates, their hydrates, their stereoisomers, their polymorphs, their racemic mixtures, their optically active forms and their use in the treatment of inflammatory conditions such as psoriasis, asthma, psoriatic arthritis or rheumatoid arthritis. Further, the present invention relates to processes of preparing such compounds, novel intermediates involved in their synthesis.

The invention provides a traditional Chinese medicine composition for treating rheumatic arthritis, a preparation and application, and belongs to the field of traditional Chinese medicines. The traditional Chinese medicine composition is prepared from the following medicinal raw materials: 12-18 parts of sailong bone, 6-12 parts of radix aconiti lateralis preparata, 3-9 parts of radix aconiti preparata, 9-15 parts of cassia twig, 1-4 parts of asarum, 9-15 parts of radix clematidis, 20-40 parts of astragalus membranaceus, 3-9 parts of scorpio, 9-15 parts of earthworm, 9-15 parts of caulis sinomenii, 12-18 parts of bighead atractylodes rhizome, 12-18 parts of poria cocos, 9-15 parts of gentiana macrophylla, 12-18 parts of angelica sinensis, 20-40 parts of caulis spatholobi, 9-15 parts of rhizoma drynariae, 12-18 parts of radix paeoniae alba, 3-9 parts of honey-fried licorice root and 6-12 parts of rhizoma zingiberis. According to the traditional Chinese medicine composition for treating rheumatic arthritis, the medicine raw material composition of the traditional Chinese medicine composition for treating rheumatic arthritis is reasonably designed, four pathological links of cold, dampness, stasis and deficiency of rheumatic arthritis are covered through precise compatibility of monarch, minister, assistant and guide, and the traditional Chinese medicine composition has triple curative effects of anti-inflammatory analgesia, immunoregulation and bone protection.